A comment on Medscape’s article discussing the risk of CVD with ADHD medication.

Cardiovascular Disease

ADHD Meds & Cardiovascular Disease

A meta-analysis of nearly 4M participants found no association between the use of medications to treat ADHD and any cardiovascular disease outcome. 

ADHD medications are known to increase heart rate and blood pressure, and as the use of ADHD medication increases in both adults and children, there has been understandable concern that ADHD meds may lead to adverse cardiovascular effects. 

But these findings suggest these medications may actually be safe for the heart. 

In the systematic review and meta-analysis, researchers analyzed 19 studies from the US, Spain, Denmark, Hong Kong, Canada, and South Korea, involving 3.9M children, adolescents, and adults. 

Researchers found no statistically significant association between ADHD and any CVD outcome among…

• Children and adolescents (pooled adjusted relative risk: 1.18)
• Young or middle-aged adults (RR: 1.04)
• Older adults (RR: 1.59)

Both stimulants and non-stimulants showed no association. When the authors looked at specific cardiovascular outcomes (such as cardiac arrest, arrhythmias, cerebrovascular diseases, or myocardial infarction) there was still no association. There was even no association among those with preexisting CVD.  

The Takeaway

Overall, the findings are reassuring and suggest these medications — which have raised concerns about CVD risk — may be safe for the heart. While the authors acknowledge that a “modest risk increase could not be ruled out,” the findings should comfort readers with cardiovascular patients being treated for ADHD.

User Experience and Cardiovascular Imaging Transformation

Check out this Change Healthcare video discussing the importance of user experience in the adoption of structured reporting, and how it can lead to improvements in imaging speed, quality, and cardiologist workflow. 

A New Standard of Cardiovascular Care

Heart disease is the leading cause of death, so it might be time to change how we think about heart attack prevention. Read Cleerly’s manifesto on why our current approach is unsustainable, how Cleerly’s AI-based platform can transform care, and what it will take to change today’s unacceptable heart disease statistics.

The Wire

• Catheter Ablation for VT Storm: For patients experiencing a ventricular tachycardia storm, early catheter ablation appears to be superior to medication, according to a new study in Circulation. Almost two years after experiencing a ventricular tachycardia storm, patients (n=129) who underwent initial catheter ablation had significantly less VA recurrence (43% vs. 92%), VT storm recurrence (28% vs. 73%), iatrogenic complications at 12 months (17% vs. 45%), CV-related hospitalizations (50% vs. 89%), and cumulative days in hospital (median 0.5 vs. 18 days). 

• FDA Approves Most Expensive Drug Ever: The FDA approved the first gene therapy for Hemophilia B, a $3.5M one-time treatment for the genetic blood-clotting disorder. Pennsylvania-based drugmaker CSL Behring raised some eyebrows when it announced the price tag of the drug, Hemgenix, but said it would ultimately reduce healthcare costs because patients would have fewer bleeding incidents and require fewer clotting treatments. 

• Rethinking HDL: A new study published in JACC investigated why coronary heart disease (CHD) risk equations consistently underperform in Black adults. During a 10 year median follow-up period looking at risk equation effectiveness among 23k CHD-free participants, low HDL-C was associated with increased CHD risk in White (HR: 1.22) but not Black (HR: 0.94) adults, and high HDL-C was not associated with decreased CHD events in either race. The authors conclude that current HDL cholesterol–based risk calculations could lead to inaccurate risk assessment for Black people.

• UltraSight Makes Cardiac Imaging Accessible: UltraSight announced new findings that its AI guidance and quality assessment technology allows medical professionals without prior sonography experience to capture high-quality diagnostic images from echo exams. Using UltraSight’s AI guidance, ten novice ultrasound users were able to capture diagnostic-quality 2D transthoracic echo images, permitting assessment of LV size, LV function, RV size, and the presence of pericardial effusion. The UltraSight software is currently under FDA review and is pending a 510(k) clearance. 

• Elevated Lp(a) Riskier than FH: A Danish study revealed that high Lp(a) levels are associated with more early cardiovascular events than having familial hypercholesterolemia (FH). While FH is considered to be the genetic disease that causes the most cases of early heart disease, this study shows that raised levels of Lp(a), which is also genetically determined, can also increase risk of early cardiovascular events. 

• Vitamin D Fails to Reduce Statin-Caused Pain: A randomized, double-blind trial of 2k participants found that vitamin D did not reduce statin-associated muscle pain, nor did it prevent people from discontinuing statin therapy. Over nearly 5 years of follow-up, participants taking statins were equally likely to develop muscle symptoms (31% vs 31%) and discontinue statin therapy (13% vs 13%), whether assigned to vitamin D or placebo groups.

• Anteris Initiates DurAVR Study: Anteris Technologies received an investigational device exemption (IDE) from the FDA, allowing the company to initiate an early feasibility study for its DurAVR transcatheter heart valve system. The study will evaluate the safety and feasibility of the TAVR product in 15 subjects in the US with severe aortic stenosis. The DurAVR is a balloon-expandable, single-piece valve designed to mimic the structure of the native human valve. 

• Heart Infections & the Opioid Epidemic: The mortality rate of infective endocarditis (IE) — a bacterial infection in the heart — in the overall US population decreased from 1999 to 2020, but doubled for young people. Researchers suspect the ongoing opioid epidemic plays a significant role in the rising incidence. Among all patients who died of IE, the percentage of people who also injected drugs increased from 1.1% in 1999 to 3.0% in 2020. Among young people who died of IE, the percentage of those who also injected drugs increased from 10.2% to 19.5%. 

• Asthma & Carotid Plaque: Persistent asthma may lead to higher carotid plaque burden, according to a new study published in AHA. Among the 5k participants, those with persistent asthma were more likely to have carotid plaque present (odds ratio: 1.83) and higher total plaque score, even after adjusting for baseline inflammatory biomarkers. 

• October Hospital Margins: Hospitals continue to face a tough outlook as we head into 2023, with Kaufman Hall’s latest National Flash Report showing that median operating margins dropped to -0.5% through October (down from -0.1% in September). The steep margin decline comes as labor expenses resumed their climb with a 3% increase in October alone (now up 10% this year), with the report also showing that hospitals are struggling to discharge patients due to internal staffing shortages and challenges at post-acute facilities.

The HeartFlow Story

Shifting the standard of care is a monumental undertaking, and yet physicians across the globe are embracing HeartFlow’s FFRct Analysis. Hear from the co-founder how HeartFlow got its start, and why physicians love it.  

Automating the Fight Against Heart Disease

See how Dr. Carolyn Lam evolved from a women’s heart health trailblazer to co-founding Us2.ai and automating the fight against heart disease.